Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 25, 2008. The report discloses a notifiable share interest in Addex Pharmaceuticals Limited, a Swiss biopharmaceuticals company.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK. The only financial data disclosed relates to a specific transaction:
- Acquisition Price: CHF 49.2807 per share.
- Shares Acquired: 6,820 common shares.
- Total Holding: 175,951 common shares (3.0% of issued capital).
- Payment Method: Cash.
Material Changes
GSK's wholly owned US subsidiary, SR One, Limited, increased its stake in Addex Pharmaceuticals Limited to 3.0%. This increase triggered a disclosure requirement under the rules of the SWX Swiss Exchange. The additional 6,820 shares were acquired in the open market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the regulatory requirement to disclose the shareholding threshold breach.
Investor Verification Points
- Verify the current market price of Addex Pharmaceuticals Limited shares on the SWX Swiss Exchange.
- Confirm the total value of the investment based on the disclosed share count and acquisition price.
- Review Addex Pharmaceuticals Limited's recent filings for any material developments related to GSK's increased stake.